Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2016–2019
DOI:
https://doi.org/10.33321/cdi.2023.47.32Abstract
-
Downloads
References
Ioannides S, Beard F, Larter N, Clark K, Wang H, Hendry A et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 2011–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.36.
Menzies R, McIntyre P, Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. Commun Dis Intell Q Rep. 2004;28(Suppl 1):S1–45.
Menzies R, Turnour C, Chiu C, McIntyre P. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 2003 to 2006. Commun Dis Intell Q Rep. 2008;32(Suppl):S2–67.
Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander People, Australia 2006-2010. Commun Dis Intell Q Rep. 2013;37(Suppl):S1–92.
Australian Institute of Health and Welfare (AIHW). Indigenous identification in hospital separations data: quality report. (Cat. no. IHW 90.) Canberra: Australian Government, AIHW; 1 May 2013. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/indigenous-australians/indigenous-identification-in-hospital-separations/contents/table-of-contents.
AIHW. Australian hospital statistics 2012–13. (Cat. no. HSE 145.) Canberra: Australian Government, AIHW; 30 April 2014. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/hospitals/australian-hospital-statistics-2012-13/contents/table-of-contents.
Bright A, Denholm J, Coulter C, Waring J, Stapledon R. Tuberculosis notifications in Australia, 2015-2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.88.
Australian Bureau of Statistics. Estimates and Projections, Aboriginal and Torres Strait Islander Australians. [Webpage.] Canberra: Australian Bureau of Statistics; 11 July 2019. [Accessed on 13 December 2021.] Available from: https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/estimates-and-projections-aboriginal-and-torres-strait-islander-australians/latest-release.
Marmot M. Social determinants and the health of Indigenous Australians. Med J Aust. 2011;194(10):512–3. doi: https://doi.org/10.5694/j.1326-5377.2011.tb03086.x.
World Health Organization (WHO). Closing the gap in a generation: health equity through action on the social determinants of health – Final report of the commission on social determinants of health. Geneva: WHO; 27 August 2008. [Accessed on 26 September 2022.] Available from: https://www.who.int/publications/i/item/WHO-IER-CSDH-08.1.
Thurber KA, Barrett EM, Agostino J, Chamberlain C, Ward J, Wade V, et al. Risk of severe illness from COVID-19 among Aboriginal and Torres Strait Islander adults: the construct of ‘vulnerable populations’ obscures the root causes of health inequities. Aust N Z J Public Health. 2021;45(6):658–63. doi: https://doi.org/10.1111/1753-6405.13172.
AIHW. Indigenous identification in hospital separations data: quality report. (Cat. no. HSE 85.) Canberra: Australian Government, AIHW; 19 February 2010. [Accessed on 29 November 2021.] Available from: https://www.aihw.gov.au/reports/hospitals/indigenous-identification-hospital-separations/contents/table-of-contents.
Australian Bureau of Statistics. Causes of Death, Australia, 2015: Explanatory Notes. Deaths of Aboriginal and Torres Strait Islander persons. (Notes 56–66.) [Webpage.] Canberra: Australian Bureau of Statistics; 28 September 2016. [Accessed on 29 November 2021.] Available from: https://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3303.0Explanatory%20Notes12015.
Australian Government Department of Health and Aged Care. Human Papillomavirus (HPV). [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2016. [Accessed on 13 December 2021.] Available from: https://www.health.gov.au/diseases/human-papillomavirus-hpv.
Kirby Institute. Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people. Annual surveillance report 2018. Sydney: University of New South Wales, Kirby Institute; 2018. Available from: https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Aboriginal-Surveillance-Report-2018.pdf.
AIHW. The burden of vaccine preventable diseases in Australia. (Cat. no. PHE 263.) Canberra: Australian Government, AIHW; 1 November 2019. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/immunisation/the-burden-of-vaccine-preventable-diseases/summary.
Little RJA, Rubin D. Chapter 3: Complete-case and available-case analysis, including weighting methods. In Statistical Analysis with Missing Data (3rd edition). Hoboken: Wiley; 2019.
Australian Government Department of Health and Aged Care. National Notifiable Diseases Surveillance System (NNDSS). [Internet.] Canberra; Australian Government Department of Health and Aged Care. [Accessed on 3 December 2021.] Available from: https://www.health.gov.au/initiatives-and-programs/nndss.
Improving Indigenous Identification in Communicable Disease Reporting Project Steering Committee. Improving Indigenous identification in communicable disease reporting systems. Adelaide: University of Adelaide, Public Health Information Development Unit; November 2004. [Accessed on 26 September 2022.] Available from: https://phidu.torrens.edu.au/pdf/1999-2004/improving_indigenous_reporting_2004.pdf.
Australian Government Department of Health and Aged Care. Hepatitis A – CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; November 2018. [Accessed on 14 December 2021.] Available from: https://www.health.gov.au/resources/publications/hepatitis-a-cdna-national-guidelines-for-public-health-units.
Australian Government Department of Health and Aged Care. Hepatitis B – CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; February 2018. [Accessed on 4 December 2021.] Available from: https://www.health.gov.au/resources/publications/hepatitis-b-cdna-national-guidelines-for-public-health-units.
Australian Government Department of Health and Aged Care. Measles – CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; May 2019. [Accessed on 14 December 2021] Available from: https://www.health.gov.au/resources/publications/measles-cdna-national-guidelines-for-public-health-units.
Australian Government Department of Health and Aged Care. Haemophilus influenzae type b invasive infection – CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; 14 April 2014. [Accessed on 14 December 2021.] Available from: https://www.health.gov.au/resources/publications/haemophilus-influenzae-type-b-invasive-infection-cdna-national-guidelines-for-public-health-units.
Australian Government Department of Health and Aged Care. Invasive meningococcal disease – CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; July 2017. [Accessed on 14 December 2021.] Available from: https://www.health.gov.au/resources/publications/invasive-meningococcal-disease-cdna-national-guidelines-for-public-health-units.
Pennington K, Enhanced Invasive Pneumococcal Disease Surveillance Working Group, Communicable Diseases Network Australia. Invasive Pneumococcal Disease Surveillance, 1 April to 30 June 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.38.
New South Wales Government Department of Health (NSW Health). Tetanus control guideline. [Internet.] Sydney: New South Wales Government, NSW Health; 1 July 2012. [Accessed on 19 May 2022.] Available from: https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/tetanus.aspx.
NSW Health. Diphtheria control guideline. [Internet.] Sydney: New South Wales Government, NSW Health; 1 January 2017. [Accessed on 19 May 2022.] Available from: https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/diphtheria.aspx.
Australian Government Department of Health and Aged Care. Influenza infection (flu) – CDNA National Guidelines For Public Health Units. Canberra: Australian Government Department of Health and Aged Care; 18 January 2019. [Accessed on 13 December 2021.] Available from: https://www.health.gov.au/resources/publications/influenza-infection-flu-cdna-national-guidelines-for-public-health-units.
NSW Health. Rotavirus control guideline. [Internet.] Sydney: New South Wales Government, NSW Health; 1 July 2018. [Accessed on 13 December 2021.] Available from: https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/rotavirus.aspx.
Australian Government Department of Health and Aged Care. Pertussis (whooping cough) – CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; March 2013. [Accessed on 14 December 2021.] Available from: https://www.health.gov.au/resources/publications/pertussis-whooping-cough-cdna-national-guidelines-for-public-health-units.
NSW Health. Mumps control guideline. [Internet.] Sydney: New South Wales Government, NSW Health. [Accessed on 13 December 2021.] Available from: https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/mumps.aspx.
Westphal DW, Eastwood A, Levy A, Davies J, Huppatz C, Gilles M et al. A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. Lancet Infect Dis. 2019;19(2):177–84. doi: https://doi.org/10.1016/S1473-3099(18)30498-5.
Walker J, Adegbija O, Smoll N, Khan A, Whicker J, Carroll H et al. Epidemiology of mumps outbreaks and the impact of an additional dose of MMR vaccine for outbreak control in regional Queensland, Australia, 2017–2018. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.67.
Schutze H, Jackson Pulver L, Harris M. What factors contribute to the continued low rates of Indigenous status identification in urban general practice? - A mixed-methods multiple site case study. BMC Health Serv Res. 2017;17(1):95. doi: https://doi.org/10.1186/s12913-017-2017-6.
Scotney A, Guthrie JA, Lokuge K, Kelly PM. “Just ask!” Identifying as Indigenous in mainstream general practice settings: a consumer perspective. Med J Aust. 2010;192(10):609. doi: https://doi.org/10.5694/j.1326-5377.2010.tb03651.x.
Kelaher M, Parry A, Day S, Paradies Y, Lawlor J, Solomon L. Improving the identification of Aboriginal and Torres Strait Islander people in mainstream general practice. Melbourne: The Lowitja Institute; Canberra: Australian National University; August 2010. Available from: http://nceph.anu.edu.au/files/kelaher_indigenous_identification_report_pdf_13237.pdf.
Rowe SL, Cowie BC. Using data linkage to improve the completeness of Aboriginal and Torres Strait Islander status in communicable disease notifications in Victoria. Aust N Z J Public Health. 2016;40(3):148–53. doi: https://doi.org/10.1111/1753-6405.12434.
AIHW. National best practice guidelines for data linkage activities relating to Aboriginal and Torres Strait Islander people: 2012. (Cat. no. IHW 74.) Canberra: Australian Government, AIHW; 9 July 2012. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/indigenous-australians/national-best-practice-guidelines-for-data-linkage/summary.
Butler DF, Myers AL. Changing epidemiology of Haemophilus influenzae in children. Infect Dis Clin North Am. 2018;32(1):119–28. doi: https://doi.org/10.1016/j.idc.2017.10.005.
Nanduri SA, Sutherland AR, Gordon LK, Santosham M. 23 – Haemophilus influenzae type b vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;301–18.e10. doi: https//doi.org/10.1016/B978-0-323-35761-6.00023-7.
McIntyre P. Vaccines against invasive Haemophilus influenzae type b disease. J Paediatr Child Health. 1994;30(1):14–8. doi: https://doi.org/10.1111/j.1440-1754.1994.tb00558.x.
Hanna JN, Wild BE. Bacterial meningitis in children under five years of age in Western Australia. Med J Aust. 1991;155(3):160–4. doi: https://doi.org/10.5694/j.1326-5377.1991.tb142183.x.
Horby P, Gilmour R, Wang H, McIntyre P. Progress towards eliminating Hib in Australia: an evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Commun Dis Intell Q Rep. 2003;27(3):324–41.
Menzies RI, Singleton RJ. Vaccine preventable diseases and vaccination policy for Indigenous populations. Pediatr Clin North Am. 2009;56(6):1263–83. doi: https://doi.org/10.1016/j.pcl.2009.09.006.
National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in Haemophilus influenzae type b (Hib) vaccination practice in Australia. Sydney: NCIRS; July 2018. [Accessed on 12 October 2021.] Available from: https://www.ncirs.org.au/sites/default/files/2018-11/Haemophilus-influenzae-type-b-history-July-2018.pdf.
Menzies RI, Bremner KM, Wang H, Beard FH, McIntyre PB. Long-term trends in invasive Haemophilus influenzae type b disease among Indigenous Australian children following use of PRP-OMP and PRP-T vaccines. Pediatr Infect Dis J. 2015;34(6):621–6. doi: https://doi.org/10.1097/INF.0000000000000681.
Ulanova M, Tsang RSW. Invasive Haemophilus influenzae disease: changing epidemiology and host–parasite interactions in the 21st century. Infect Genet Evol. 2009;9(4):594–605. doi: https://doi.org/10.1016/j.meegid.2009.03.001.
Jacups SP, Morris PS, Leach AJ. Haemophilus influenzae type b carriage in Indigenous children and children attending childcare centers in the Northern Territory, Australia, spanning pre- and post-vaccine eras. Vaccine. 2011;29(16):3083–8. doi: https://doi.org/10.1016/j.vaccine.2010.09.030.
Guthridge S, McIntyre P, Isaacs D, Hanlon M, Patel M. Differing serologic responses to an Haemophilus influenzae type b polysaccharide–Neisseria meningitidis outer membrane protein conjugate (PRP–OMPC) vaccine in Australian Aboriginal and Caucasian infants — implications for disease epidemiology. Vaccine. 2000;18(23):2584–91. doi: https://doi.org/10.1016/s0264-410x(99)00549-6.
Maguire JE, Beard F, Meder K, Dey A, Macartney K, McIntyre P. Australian vaccine preventable disease epidemiological review series: invasive Haemophilus influenzae type b disease, 2000-2017. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.11.
Averhoff FM, Khudyakov Y, Nelson NP. 24 – Hepatitis A vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;319–41.e15. doi: https//doi.org/10.1016/B978-0-323-35761-6.00024-9.
World Health Organisation (WHO). WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec. 2012;87(28/29):261–76.
Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28(41):6653–7. doi: https://doi.org/10.1016/j.vaccine.2010.08.037.
Franklin N, Camphor H, Wright R, Stafford R, Glasgow K, Sheppeard V. Outbreak of hepatitis A genotype IB in Australia associated with imported frozen pomegranate arils. Epidemiol Infect. 2019;147:e74. doi: https://doi.org/10.1017/S0950268818003515.
NSW Health. Hepatitis A linked to imported frozen pomegranate. [Internet.] Sydney: New South Wales Government, NSW Health; 8 June 2018. [Accessed on 29 November 2021.] Available from: https://www.health.nsw.gov.au/Infectious/alerts/Pages/hep-A-pomegranate.aspx.
Victorian Government Department of Health. Hepatitis A risk in Victoria [Internet.] Melbourne: Victorian Government Department of Health; 20 December 2021. [Accessed on 1 April 2022.] Available from: https://www.health.vic.gov.au/infectious-diseases/hepatitis-a-risk-in-victoria.
NSW Health. OzFoodNet: Enhancing Foodborne Disease Surveillance Across Australia. NSW Annual Report 2017. Sydney: New South Wales Government, NSW Health, Communicable Diseases Branch; July 2018. [Accessed on 29 November 2021.] Available from: https://www.health.nsw.gov.au/Infectious/foodborne/Publications/nsw-ofn-annual-report-2017.pdf.
NSW Health. OzFoodNet: Enhancing Foodborne Disease Surveillance Across Australia. NSW Annual Report 2016. Sydney: New South Wales Government, NSW Health, Communicable Diseases Branch; April 2017. [Accessed on 29 November 2021.] Available from: https://www.health.nsw.gov.au/Infectious/foodborne/Publications/nsw-ofn-annual-report-2016.pdf.
NSW Health. Hepatitis A outbreak related to person-to-person transmission in Sydney 2017/18. [Internet.] Sydney: New South Wales Government, NSW Health. [Accessed on 29 November 2021.] Available from: https://www.health.nsw.gov.au/Infectious/alerts/Pages/hep-A-outbreak-person-to-person.aspx.
Tasmanian Government Department of Health. Hepatitis A vaccine for at risk groups. [Internet.] Hobart: Tasmanian Government Department of Health; 2019. [Accessed on 29 November 2021.] Available from: https://www.health.tas.gov.au/news/2019/hepatitis_a_vaccine_for_at_risk_groups.
Victorian Government Department of Health. Hepatitis A outbreak. [Internet.] Melbourne: Victorian Government Department of Health; 20 August 2020. [Accessed on 29 November 2021.] Available from: https://www.health.vic.gov.au/health-advisories/hepatitis-a-outbreak-0.
Thompson C, Dey A, Fearnley E, Polkinghorne B, Beard F. Impact of the national targeted Hepatitis A immunisation program in Australia: 2000–2014. Vaccine. 2017;35(1):170–6. doi: https://doi.org/10.1016/j.vaccine.2016.11.002.
Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. [Website.] Canberra: Australian Government Department of Health and Aged Care. Available from: https://immunisationhandbook.health.gov.au/contents.
Vodstrcil LA, Fairley CK, Williamson DA, Bradshaw CS, Chen MY, Chow EPF. Immunity to hepatitis A among men who have sex with men attending a large sexual health clinic in Melbourne, Australia, 2012–2018. Sex Transm Infect. 2020;96(4):265–70. doi: https://doi.org/10.1136/sextrans-2019-054327.
Heywood AE, Nothdurft H, Tessier D, Moodley M, Rombo L, Marano C et al. Pre-travel advice, attitudes and hepatitis A and B vaccination rates among travellers from seven countries. J Travel Med. 2016;24(1):taw069. doi: https://doi.org/10.1093/jtm/taw069.
Van Damme P, Ward JW, Shouval D, Zanetti A. 25 – Hepatitis B vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;342–74.e17. doi: https//doi.org/10.1016/B978-0-323-35761-6.00025-0.
Amin J, O’Connell D, Bartlett M, Tracey E, Kaldor J, Law M et al. Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study. Aust N Z J Public Health. 2007;31(5):475–82. doi: https://doi.org/10.1111/j.1753-6405.2007.00121.x.
Graham S, Maclachlan JH, Gunaratnam P, Cowie BC. Chronic hepatitis B prevalence in Australian Aboriginal and Torres Strait Islander people before and after implementing a universal vaccination program: a systematic review and meta-analysis. Sex Health. 2019;16(3):201–11. doi: https://doi.org/10.1071/SH18150.
Davies J, Li SQ, Tong SY, Baird RW, Beaman M, Higgins G et al. Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population. PLoS One. 2017;12(9):e0184082. doi: https://doi.org/10.1371/journal.pone.0184082.
Reekie J, Kaldor JM, Mak DB, Ward J, Donovan B, Hocking JS et al. Long-term impact of childhood hepatitis B vaccination programs on prevalence among Aboriginal and non-Aboriginal women giving birth in Western Australia. Vaccine. 2018;36(23):3296–300. doi: https://doi.org/10.1016/j.vaccine.2018.04.057.
Connelly M, Bruce MG, Bulkow L, Snowball M, McMahon BJ. The changing epidemiology and aetiology of hepatocellular carcinoma from 1969 through 2013 in Alaska Native people. Liver Int. 2016;36(12):1829–35. doi: https://doi.org/10.1111/liv.13173.
Mohammed H, McMillan M, Marshall HS. Social and behavioral predictors of two-doses 4CMenB vaccine series among adolescents enrolled in a cluster randomized controlled trial in Australia. Hum Vaccin Immunother. 2021;18(1):1953345. doi: https://doi.org/10.1080/21645515.2021.1953345.
Brotherton JM, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust. 2013;199(9):614–7. doi: https://doi.org/10.5694/mja13.10272.
Cheah BC, Davies J, Singh GR, Wood N, Jackson K, Littlejohn M et al. Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia. Vaccine. 2018;36(24):3533–40. doi: https://doi.org/10.1016/j.vaccine.2018.01.062.
Narayana S, Nugent M, Woodman R, Larkin M, Ramachandran J, Muller K et al. Quality measures for hepatitis B in a remote Australian Aboriginal community. J Gastroenterol Hepatol. 2020;35(Suppl):54. doi: https://doi.org/10.1111/jgh.15269.
Wattiaux AL, Yin JK, Beard F, Wesselingh S, Cowie B, Ward J et al. Hepatitis B immunization for indigenous adults, Australia. Bull World Health Organ. 2016;94(11):826–34A. doi: https://doi.org/10.2471/BLT.16.169524.
Wigg AJ, Narayana SK, Hartel G, Medlin L, Pratt G, Powell EE et al. Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. EClinicalMedicine. 2021;36:100919. doi: https://doi.org/10.1016/j.eclinm.2021.100919.
Parker C, Tong SY, Dempsey K, Condon J, Sharma SK, Chen JW et al. Hepatocellular carcinoma in Australia’s Northern Territory: high incidence and poor outcome. Med J Aust. 2014;201(8):470–4. doi: https://doi.org/10.5694/mja13.11117.
Condon JR, Zhang X, Dempsey K, Garling L, Guthridge S. Trends in cancer incidence and survival for Indigenous and non-Indigenous people in the Northern Territory. Med J Aust. 2016;205(10):454–8. doi: https://doi.org/10.5694/mja16.00588.
AIHW. Cancer in Aboriginal and Torres Strait Islander people of Australia. (Cat. no. CAN 109.) [Web report.] Canberra: Australian Government, AIHW; 15 March 2018. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/cancer/cancer-in-indigenous-australians.
Bouvard V, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F et al. A review of human carcinogens—part B: biological agents. Lancet Oncol. 2009;10(4):321–2. doi: https://doi.org/10.1016/s1470-2045(09)70096-8.
AIHW. National Cervical Screening Program monitoring report 2021. (Cat. no. CAN 141.) Canberra: Australian Government, AIHW; 3 December 2021. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/cancer-screening/national-cervical-screening-program-monitoring-rep/formats.
Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW et al. Human papillomavirus prevalence among Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program. BMC Medicine. 2011;9(1):104. doi: https://doi.org/10.1186/1741-7015-9-104.
Whop LJ, Garvey G, Baade P, Cunningham J, Lokuge K, Brotherton JM et al. The first comprehensive report on Indigenous Australian women’s inequalities in cervical screening: a retrospective registry cohort study in Queensland, Australia (2000-2011). Cancer. 2016;122(10):1560–9. doi: https://doi.org/10.1002/cncr.29954.
Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4. doi: https://doi.org/10.1097/OLQ.0000000000000193.
National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Cervical Cancer Control (C4). 2021 Cervical Cancer Elimination Progress Report: Australia’s progress towards the elimination of cervical cancer as a public health problem. Melbourne: NHMRC C4; 26 March 2021. Available from: https://www.cervicalcancercontrol.org.au/wp-content/uploads/2021/03/2021-C4-CRE-Elim-Report.pdf.
Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D et al. Assessment of herd immunity and cross-protection following a human papillomavirus vaccination programme: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(190):958–66. doi: https://doi.org/10.1016/S1473-3099(14)70841-2.
Machalek DA, Garland SM, Brotherton JML, Bateson D, McNamee K, Stewart M et al. Very low prevalence of vaccine human papillomavirus (HPV) types among 18- to 35-year old Australian women, nine years following implementation of vaccination. J Infect Dis. 2018;217(10):1590–600. doi: https://doi.org/10.1093/infdis/jiy075.
McGregor S, Saulo D, Brotherton JML, Liu B, Phillips S, Skinner SR et al. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: the VIP-I study. Vaccine. 2018;36(29):4311–6. doi: https://doi.org/10.1016/j.vaccine.2018.05.104.
Jamieson LM, Antonsson A, Garvey G, Ju X, Smith M, Logan RM et al. Prevalence of oral human papillomavirus infection among Australian Indigenous adults. JAMA Netw Open. 2020;3(6):e204951. doi: https://doi.org/10.1001/jamanetworkopen.2020.4951.
Antonsson A, Cornford M, Perry S, Davis M, Dunne MP, Whiteman DC. Prevalence and risk factors for oral HPV infection in young Australians. PLoS One. 2014;9(3):e91761. doi: https://doi.org/10.1371/journal.pone.0091761.
Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and Indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015;211(1):91–9. doi: https://doi.org/10.1093/infdis/jiu370.
Ali H, McManus H, O Connor CC, Callander D, Kong M, Graham S et al. Human papillomavirus vaccination and genital warts in young indigenous Australians: national sentinel surveillance data. Med J Aust. 2017;206(5):204–9. doi: https://doi.org/10.5694/mja16.00597.
Kirby Institute. National update on HIV, viral hepatitis and sexually transmissible infections in Australia 2009–2018. Sydney: University of New South Wales, Kirby Institute; 4 November 2020. Available from: https://kirby.unsw.edu.au/report/national-update-hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-2009-2018.
Australian Bureau of Statistics. Estimates of Aboriginal and Torres Strait Islander Australians (June 2016). [Webpage.] Canberra; Australian Bureau of Statistics; 31 August 2018. Available from: https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/estimates-aboriginal-and-torres-strait-islander-australians/jun-2016.
AIHW. Cervical screening in Australia 2019. (Cat. no. CAN 124.) Canberra: Australian Government, AIHW; 6 May 2019. [Accessed on 19 May 2022.] Available from: https://www.aihw.gov.au/reports/cancer-screening/cervical-screening-in-australia-2019/summary.
Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016;204(5):184–e1. doi: https://doi.org/10.5694/mja15.01038.
AIHW. National Cervical Screening Program monitoring report 2019. (Cat. no. CAN 132.) Canberra: Australian Government, AIHW; 2 December 2019. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/cancer-screening/national-cervical-screening-monitoring-2019/data.
Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208–12. doi: https://doi.org/10.1093/infdis/jix498.
Drolet M, Laprise J-F, Brotherton JML, Donovan B, Fairley CK, Ali H et al. The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation. J Infect Dis. 2017;216(10):1205–9. doi: https://doi.org/10.1093/infdis/jix476.
Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32 pt A):4768–73. doi: https://doi.org/10.1016/j.vaccine.2017.12.079.
Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80. doi: https://doi.org/10.1016/S1473-3099(14)71073-4.
Australian Government Department of Health and Aged Care. National Cervical Screening Program. [Internet.] Canberra: Australian Government Department of Health and Aged Care. [Accessed on 29 May 2018.] Available from: https://www.health.gov.au/initiatives-and-programs/national-cervical-screening-program.
National Pathology Accreditation Advisory Council (NPAAC). The requirements for laboratories reporting tests for the National Cervical Screening Program (2nd edition). Canberra: Australian Government Department of Health and Aged Care; 26 September 2019. [Accessed on 19 May 2022.] Available from: https://www1.health.gov.au/internet/main/publishing.nsf/Content/npaac-cervical-screening.
World Health Organization (WHO). Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 17 November 2020. Available from: https://www.who.int/publications/i/item/9789240014107.
Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JML, Saville M et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):e19–27. doi: https://doi.org/10.1016/S2468-2667(18)30183-X.
Whop LJ, Smith MA, Butler TL, Adcock A, Bartholomew K, Goodman MT et al. Achieving cervical cancer elimination among Indigenous women. Prev Med. 2021;144:106314. doi: https://doi.org/10.1016/j.ypmed.2020.106314.
Zambon M. Influenza and other emerging respiratory viruses. Medicine (Abingdon). 2014;42(1):45–51. doi: https://doi.org/10.1016/j.mpmed.2013.10.017.
Luke CJ, Lakdawala SS, Subbarao K. 32 – Influenza vaccine - live. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;489–510.e7. doi: https//doi.org/10.1016/B978-0-323-35761-6.00032-8.
Li-Kim-Moy J, Yin JK, Patel C, Beard FH, Chiu C, Macartney KK et al. Australian vaccine preventable disease epidemiological review series: influenza 2006 to 2015. Commun Dis Intell Q Rep. 2016;40(4):E482–95.
Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–30. doi: https://doi.org/10.1016/S0140-6736(11)61051-9.
Mertz D, Lo CKF, Lytvyn L, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis. BMC Infect Dis. 2019;19(1):683. doi: https://doi.org/10.1186/s12879-019-4318-3.
Tenforde MW, Kondor RJG, Chung JR, Zimmerman RK, Nowalk MP, Jackson ML et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States – 2019–2020. Clin Infect Dis. 2021;73(11):e4244–50. doi: https://doi.org/10.1093/cid/ciaa1884.
Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3. doi: https://doi.org/10.1038/s41572-018-0002-y.
Moa A, Trent M, Menzies R. Severity of the 2019 influenza season in Australia – a comparison between 2017 and 2019 H3N2 influenza seasons. Global Biosecurity. 2019;1(3). Available from: https://jglobalbiosecurity.com/articles/10.31646/gbio.47/.
Cheng AC, Holmes M, Dwyer DE, Senanayake S, Cooley L, Irving LB et al. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN). Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.48.
Moberley S, Carlson S, Durrheim D, Dalton C. Flutracking: Weekly online community-based surveillance of influenza-like illness in Australia, 2017 Annual Report. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.31.
Strebel PM, Papania MJ, Gastañaduy PA, Goodson JL. 37 – Measles vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;579–618.e21. doi: https//doi.org/10.1016/B978-0-323-35761-6.00037-7.
Guerra FM, Crowcroft NS, Friedman L, Deeks SL, Halperin SA, Severini A et al. Waning of measles maternal antibody in infants in measles elimination settings – a systematic literature review. Vaccine. 2018;36(10):1248–55. doi: https://doi.org/10.1016/j.vaccine.2018.01.002.
Winkler NE, Dey A, Quinn HE, Pourmarzi D, Lambert S, McIntyre P et al. Australian vaccine preventable disease epidemiological review series: measles, 2012–2019. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.38.
Hull BP, Beard FH, Hendry AJ, Dey A, Macartney K. “No jab, no pay”: catch-up vaccination activity during its first two years. Med J Aust. 2020;213(8):364–9. doi: https://doi.org/10.5694/mja2.50780.
Craig AT, Heywood AE, Worth H. Measles epidemic in Samoa and other Pacific islands. Lancet Infect Dis. 2020;20(3):273–5. doi: https://doi.org/10.1016/S1473-3099(20)30053-0.
Paules CI, Marston HD, Fauci AS. Measles in 2019 – going backward. N Engl J Med. 2019;380(23):2185–7. doi: https://doi.org/10.1056/NEJMp1905099.
Northern Territory Government Department of Health (NT Health). Measles Update – Vaccination program extended. [Internet.] Darwin: NT Health; 28 March 2019. [Accessed on 3 December 2021.] Available from: https://health.nt.gov.au/news/pre-2020/measles-update-vaccination-program-extended.
NCIRS. History of immunisation in Australia. [Internet.] Sydney: NCIRS; February 2022. [Accessed on 4 April 2022.] Available from: https://ncirs.org.au/health-professionals/history-immunisation-australia.
Granoff DM, Pollard AJ, Harrison LH. 39 – Meningococcal capsular group B vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;644–62.e6. doi: https//doi.org/10.1016/B978-0-323-35761-6.00053-5.
Harrison LH, Granoff DM, Pollard AJ. 38 – Meningococcal capsular group A, C, W, and Y conjugate vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;619–43.e11. doi: https//doi.org/10.1016/B978-0-323-35761-6.00038-9.
Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–82. doi: https://doi.org/10.1016/j.vaccine.2019.04.020.
Wang B, Clarke M, Thomas N, Howell S, Haji Ali Afzali H, Marshall H. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr Infect Dis J. 2014;33(3):316–8. doi: https://doi.org/10.1097/INF.0000000000000043.
Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774-83. doi: https://doi.org/10.1016/S1474-4422(12)70180-1.
Strifler L, Morris SK, Dang V, Tu HAT, Minhas RS, Jamieson FB et al. The health burden of invasive meningococcal disease: a systematic review. J Pediatric Infect Dis Soc. 2016;5(4):417–30. doi: https://doi.org/10.1093/jpids/piv065.
Sudbury EL, O’Sullivan S, Lister D, Varghese D, Satharasinghe K. Case manifestations and public health response for outbreak of meningococcal W disease, Central Australia, 2017. Emerg Infect Dis. 2020;26(7):1355–63. doi: https://doi.org/10.3201/eid2607.181941.
Sharma K, Chiu C, Wood N. Meningococcal vaccines in Australia: a 2019 update. Aust Prescr. 2019;42(4):131–5. doi: https://doi.org/10.18773/austprescr.2019.042.
Archer BN, Chiu CK, Jayasinghe SH, Richmond PC, McVernon J, Lahra MM et al. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination. Med J Aust. 2017;207(9):382–7. doi: https://doi.org/10.5694/mja16.01340.
Baker M, McNicholas A, Garrett N, Jones N, Stewart J, Koberstein V et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J. 2000;19(10):983–90. doi: https://doi.org/10.1097/00006454-200010000-00009.
Murray RL, Britton J, Leonardi-Bee J. Second hand smoke exposure and the risk of invasive meningococcal disease in children: systematic review and meta-analysis. BMC Public Health. 2012;12:1062. doi: https://doi.org/10.1186/1471-2458-12-1062.
Pharmaceutical Benefits Advisory Committee (PBAC). Public Summary Document – November 2019 PBAC Meeting. 7.05 Multicomponent meningococcal group B vaccine. Canberra: Australian Government Department of Health and Aged Care; 2020. [Accessed on 19 May 2022.] Available from: https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2019-11/files/multicomponent-meningococcal-b-vaccine-psd-november-2019.pdf.
Marshall HS, Lally N, Flood L, Phillips P. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med J Aust. 2020;212(2):89–93. doi: https://doi.org/10.5694/mja2.50481.
Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–27. doi: https://doi.org/10.1056/NEJMoa1900236.
Patel C, Chiu CK, Beard FH, Crawford NW, Macartney K. One disease, two vaccines: challenges in prevention of meningococcal disease. Med J Aust. 2020;212(10):453–6.e1. doi: https://doi.org/10.5694/mja2.50567.
Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371(9616):932–44. doi: https://doi.org/10.1016/S0140-6736(08)60419-5.
Rubin SA. 40 – Mumps vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;663–88.e11. doi: https//doi.org/10.1016/B978-0-323-35761-6.00039-0.
Westphal D. Vaccine effectiveness during a large mumps outbreak in Western Australia. [Conference presentation.] Public Health Association of Australia (PHAA), 15th National Immunisation Conference: ‘Immunisation: the jigsaw - fitting the pieces two decades on’. Brisbane: Brisbane Convention and Exhibition Centre; 8 June 2016.
Bag SK, Dey A, Wang H, Beard FH. Australian vaccine preventable disease epidemiological review series: mumps 2008–2012. Commun Dis Intell Q Rep. 2015;39(1):E10–8.
Bangor-Jones RD, Dowse GK, Giele CM, Van Buynder PG, Hodge MM, Whitty MM. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust. 2009;191(7):398–401. doi: https://doi.org/10.5694/j.1326-5377.2009.tb02850.x.
Centers for Disease Control and Prevention (CDC). Mumps cases and outbreaks. [Internet.] Atlanta: Federal Government of the United States of America, United States Department of Health and Human Services, CDC. [Accessed on 30 June 2020.] Available from: https://www.cdc.gov/mumps/outbreaks.html.
Fields VS, Safi H, Waters C, Dillaha J, Capelle L, Riklon S et al. Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak report. Lancet Infect Dis. 2019;19(2):185-92. doi: https://doi.org/10.1016/S1473-3099(18)30607-8.
Shah M, Quinlisk P, Weigel A, Riley J, James L, Patterson J et al. Mumps outbreak in a highly vaccinated university-affiliated setting before and after a measles-mumps-rubella vaccination campaign—Iowa, July 2015 – May 2016. Clin Infect Dis. 2018;66(1):81–8. doi: https://doi.org/10.1093/cid/cix718.
Albertson JP, Clegg WJ, Reid HD, Arbise BS, Pryde J, Vaid A et al. Mumps outbreak at a university and recommendation for a third dose of measles-mumps-rubella vaccine – Illinois, 2015–2016. MMWR Morb Mortal Wkly Rep. 2016;65(29):731–4. doi: https://doi.org/10.15585/mmwr.mm6529a2.
Deeks SL, Lim GH, Simpson MA, Gagne L, Gubbay J, Kristjanson E et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ. 2011;183(9):1014–20. doi: https://doi.org/10.1503/cmaj.101371.
Indenbaum V, Hübschen JM, Stein-Zamir C, Mendelson E, Sofer D, Hindiyeh M et al. Ongoing mumps outbreak in Israel, January to August 2017. Euro Surveill. 2017;22(35):30605. doi: https://doi.org/10.2807/1560-7917.ES.2017.22.35.30605.
Willocks LJ, Guerendiain D, Austin HI, Morrison KE, Cameron RL, Templeton KE et al. An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland. Epidemiol Infect. 2017;145(15):3219–25. doi: https://doi.org/10.1017/S0950268817002102.
Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;4(4):CD004407. doi: https://doi.org/10.1002/14651858.CD004407.pub4.
Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, Cohen D et al. Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations? Epidemiol Infect. 2013;141(3):651–66. doi: https://doi.org/10.1017/S0950268812001136.
Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. N Engl J Med. 2017;377(10):947–56. doi: https://doi.org/10.1056/NEJMoa1703309.
Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep. 2018;67(1):33–8. doi: https://doi.org/10.15585/mmwr.mm6701a7.
Patel C, Beard F, Hendry A, Quinn H, Dey A, Macartney K et al. Australian mumps serosurvey 2012–2013: any cause for concern? Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.67.
Gidding HF, Quinn HE, Hueston L, Dwyer DE, McIntyre PB. Declining measles antibodies in the era of elimination: Australia’s experience. Vaccine. 2018;36(4):507–13. doi: https://doi.org/10.1016/j.vaccine.2017.12.002.
Edirisuriya C, Beard FH, Hendry AJ, Dey A, Gidding HF, Hueston L et al. Australian rubella serosurvey 2012–2013: on track for elimination? Vaccine. 2018;36(20):2794–8. doi: https://doi.org/10.1016/j.vaccine.2018.03.086.
Anderson RM. The concept of herd immunity and the design of community-based immunization programmes. Vaccine. 1992;10(13):928–35. doi: https://doi.org/10.1016/0264-410x(92)90327-g.
Edwards KM, Decker MD. 44 – Pertussis vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;711–61.e16. doi: https//doi.org/10.1016/B978-0-323-35761-6.00043-2.
Lovie-Toon YG, Hall KK, Chang AB, Anderson J, O’Grady KAF. Immunisation timeliness in a cohort of urban Aboriginal and Torres Strait Islander children. BMC Public Health. 2016;16(1):1159. doi: https://doi.org/10.1186/s12889-016-3825-z.
Moore HC, Fathima P, Gidding HF, de Klerk N, Liu B, Sheppeard V et al. Assessment of on-time vaccination coverage in population subgroups: a record linkage cohort study. Vaccine. 2018;36(28):4062–9. doi: https://doi.org/10.1016/j.vaccine.2018.05.084.
Gidding HF, Flack LK, Andrews RM, Snelling TL, McIntyre PB, Moore HC et al. Infant, maternal and demographic predictors of delayed vaccination: a population-based cohort study. Vaccine. 2020;38(38):6057–64. doi: https://doi.org/10.1016/j.vaccine.2019.09.091.
Krishnaswamy S, Cheng AC, Wallace EM, Buttery J, Giles ML. Understanding the barriers to uptake of antenatal vaccination by women from culturally and linguistically diverse backgrounds: a cross-sectional study. Hum Vaccin Immunother. 2018;14(7):1591–8. doi: https://doi.org/10.1080/21645515.2018.1445455.
Lotter K, Regan AK, Thomas T, Effler PV, Mak DB. Antenatal influenza and pertussis vaccine uptake among Aboriginal mothers in Western Australia. Aust N Z J Obstet Gynaecol. 2018;58(4):417–24. doi: https://doi.org/10.1111/ajo.12739.
McHugh L, Andrews RM, Leckning B, Snelling T, Binks MJ. Baseline incidence of adverse birth outcomes and infant influenza and pertussis hospitalisations prior to the introduction of influenza and pertussis vaccination in pregnancy: a data linkage study of 78 382 mother-infant pairs, Northern Territory, Australia, 1994–2015. Epidemiol Infect. 2019;147:e233. doi: https://doi.org/10.1017/S0950268819001171.
McHugh L, Crooks K, Creighton A, Binks M, Andrews RM. Safety, equity and monitoring: a review of the gaps in maternal vaccination strategies for Aboriginal and Torres Strait Islander women. Hum Vaccin Immunother. 2020;16(2):371–6. doi: https://doi.org/10.1080/21645515.2019.1649552.
Marshall KS, Quinn HE, Pillsbury AJ, Maguire JE, Lucas RM, Dey A et al. Australian vaccine preventable disease epidemiological review series: pertussis, 2013–2018. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.3.
Rowe SL, Perrett KP, Morey R, Stephens N, Cowie BC, Nolan TM et al. Influenza and pertussis vaccination of women during pregnancy in Victoria, 2015–2017. Med J Aust. 2019;210(10):454–62. doi: https://doi.org/10.5694/mja2.50125.
Laurie L, Lambert SB, Jones L, Boddy G, O’Grady KAF. Influenza and pertussis vaccine uptake during pregnancy among Australian women in south-east Queensland, Australia. Aust N Z J Public Health. 2021;45(5):443–8. doi: https://doi.org/10.1111/1753-6405.13133.
Liu BC, McIntyre P, Kaldor JM, Quinn HE, Ridda I, Banks E. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis. 2012;55(11):1450–6. doi: https://doi.org/10.1093/cid/cis627.
Cortese M, Baughman A, Brown K, Srivastava P. A “new age” in pertussis prevention: new opportunities through adult vaccination. Am J Prev Med. 2007;32(3):177–85. doi: https://doi.org/10.1016/j.amepre.2006.10.015.
McHugh L, Viney KA, Andrews RM, Lambert SB. Pertussis epidemiology prior to the introduction of a maternal vaccination program, Queensland Australia. Epidemiol Infect. 2018;146(2):207–17. doi: https://doi.org/10.1017/S0950268817002722.
Jardine A, Conaty SJ, Lowbridge C, Thomas J, Staff M, Vally H. Who gives pertussis to infants? Source of infection for laboratory confirmed cases less than 12 months of age during an epidemic, Sydney, 2009. Commun Dis Intell Q Rep. 2010;34(2):116–21.
Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. mBio. 2020;11(3):e00937-20. doi: https://doi.org/10.1128/mBio.00937-20.
Grabenstein JD, Musher DM. 47 – Pneumococcal polysaccharide vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;216-840. doi: https//doi.org/10.1016/B978-0-323-35761-6.00046-8.
Cook HM, Giele CM, Jayasinghe SH, Wakefield A, Krause VL. An outbreak of serotype-1 sequence type 306 invasive pneumococcal disease in an Australian Indigenous population. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.66.
Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V et al. Long-term impact of a “3 + 0” schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002–2014. Clin Infect Dis. 2017;64(2):175–83. doi: https://doi.org/10.1093/cid/ciw720.
Jayasinghe S, Chiu C, Menzies R, Lehmann D, Cook H, Giele C et al. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children. Vaccine. 2015;33(48):6666–74. doi: https://doi.org10.1016/j.vaccine.2015.10.089.
Lowbridge C, McIntyre PB, Gilmour R, Chiu C, Seale H, Ferson MJ et al. Long term population impact of seven-valent pneumococcal conjugate vaccine with a “3+0’’ schedule—How do “2+1’’ and “3+1’’ schedules compare? Vaccine. 2015;33(28):3234–41. doi: https://doi.org/10.1016/j.vaccine.2015.04.079.
Collins DA, Hoskins A, Snelling T, Senasinghe K, Bowman J, Stemberger NA et al. Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian Aboriginal population. Pneumonia (Nathan). 2017;9:14. doi: https://doi.org/10.1186/s41479-017-0038-x.
Blyth CC, Jayasinghe S, Andrews RM. A rationale for change: an increase in invasive pneumococcal disease in fully vaccinated children. Clin Infect Dis. 2020;70(4):680–3. doi: https://doi.org/10.1093/cid/ciz493.
Australian Bureau of Statistics. National Aboriginal and Torres Strait Islander Health Survey. [Webpage.] Canberra: Australian Bureau of Statistics; 11 December 2019. [Accessed on 21 February 2022.] Available from: https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-survey/2018-19.
Tran C, Chiu C, Cheng AC, Crawford NW, Gilles ML, Macartney KK et al. ATAGI 2021 annual statement on immunisation. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.60.
Pennington K, Enhanced Invasive Pneumococcal Disease Surveillance Working Group, Communicable Diseases Network Australia. Invasive Pneumococcal Disease Surveillance. 1 July to 30 September 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.40.
Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9. doi: https://doi.org/10.1016/S1473-3099(14)71081-3.
Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–43. doi: https://doi.org/10.1016/S1473-3099(15)70044-7.
Menzies R, Stein AN, Booy R, Van Buynder PG, Litt J, Cripps AW. The impact of the changing pneumococcal national immunisation program among older Australians. Vaccine. 2021;39(4):720–8. doi: https://doi.org/10.1016/j.vaccine.2020.12.025.
Strachan R, Homaira N, Beggs S, Bhuiyan MU, Gilbert GL, Lambert SB et al. Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. Thorax. 2021;76(5):487–93. doi: https://doi.org/10.1136/thoraxjnl-2020-216032.
Choi EH, Zhang F, Lu YJ, Malley R. Capsular polysaccharide (CPS) release by serotype 3 pneumococcal strains reduces the protective effect of anti-type 3 CPS antibodies. Clin Vaccine Immunol. 2016;23(2):162–7. doi: https://doi.org/10.1128/CVI.00591-15.
Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505. doi: https://doi.org/10.1542/peds.2009-3027.
Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530–9. doi: https://doi.org/10.1080/21645515.2018.1532249.
Thompson A, Lamberth E, Severs J, Scully I, Tarabar S, Ginis J et al. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019;37(42):6201–7. doi: https://doi.org/10.1016/j.vaccine.2019.08.048.
Collins DA, Hoskins A, Bowman J, Jones J, Stemberger NA, Richmond PC et al. High nasopharyngeal carriage of non-vaccine serotypes in Western Australian Aboriginal people following 10 years of pneumococcal conjugate vaccination. PLoS One. 2013;8(12):e82280. doi: https://doi.org/10.1371/journal.pone.0082280.
Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA pediatrics. 2018;172(10):958–65. doi: https://doi.org/10.1001/jamapediatrics.2018.1960.
Parashar UD, Cortese MM, Offit PA. 52 – Rotavirus Vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;950–69.e11. doi: https//doi.org/10.1016/B978-0-323-35761-6.00051-1.
Donato CM, Roczo-Farkas S, Kirkwood CD, Barnes GL, Bines JE. Rotavirus disease and genotype diversity in older children and adults in Australia. J Infect Dis. 2022;225(12):2116–26. doi: https://doi.org/10.1093/infdis/jiaa430.
Queensland Government Department of Health (Queensland Health). Rotavirus in Queensland, 2006–2017. Brisbane: Queensland Health; 2017. [Accessed on 26 September 2022.] Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0025/675502/rotavirus-2017-report.pdf.
Maguire J, Glasgow K, Glass K, Roczo-Farkas S, Bines JE, Sheppeard V et al. Rotavirus epidemiology and monovalents rotavirus vaccine effectiveness in Australia: 2010–2017. Pediatrics. 2019;144(4):e20191024. doi: https://doi.org/10.1542/peds.2019-1024.
Roczo-Farkas S, Cowley D, Bines JE. Australian Rotavirus Surveillance Program: Annual Report, 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.28.
Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis. 2011;52(2):191–9. doi: https://doi.org/10.1093/cid/ciq101.
Whiley DM, Ye S, Tozer S, Clark JE, Bletchly C, Lambert SB et al. Over-diagnosis of rotavirus infections in infants due to detection of vaccine virus. Clin Infect Dis. 2020;71(5):1324–6. doi: https://doi.org/10.1093/cid/ciz1196.
Hsieh YC, Wu FT, Hsiung CA, Wu HS, Chang KY, Huang YC. Comparison of virus shedding after lived attenuated and pentavalent reassortant rotavirus vaccine. Vaccine. 2014;32(10):1199–204. doi: https://doi.org/10.1016/j.vaccine.2013.08.041.
Lee B, Colgate ER. Rotavirus epidemiology and vaccine effectiveness: continuing successes and ongoing challenges. Pediatrics. 2019;144(4):e20192426. doi: https://doi.org/10.1542/peds.2019-2426.
Gracey M, Lee AH, Yau KKW. Hospitalisation for gastroenteritis in Western Australia. Arch Dis Child. 2004;89(8):768–72. doi: https://doi.org/10.1136/adc.2003.037531.
Srinivasjois R, Slimings C, Einarsdóttir K, Burgner D, Leonard H. Association of gestational age at birth with reasons for subsequent hospitalisation: 18 years of follow-Up in a Western Australian population study. PLoS One. 2015;10(6):e0130535. doi: https://doi.org/10.1371/journal.pone.0130535.
Carville KS, Lehmann D, Hall G, Moore H, Richmond P, de Klerk N et al. Infection is the major component of the disease burden in Aboriginal and non-Aboriginal Australian children: a population-based study. Pediatr Infect Dis J. 2007;26(3):210–6. doi: https://doi.org/10.1097/01.inf.0000254148.09831.7f.
Hull B, Hendry A, Dey A, Beard F, Brotherton J, McIntyre P. Annual Immunisation Coverage Report 2016. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.44.
Hull B, Hendry A, Dey A, Macartney K, Beard F. Immunisation Coverage Annual Report 2019. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2020.45.18.
Fathima P, Gidding HF, Snelling TL, McIntyre PB, Blyth CC, Sheridan S et al. Timeliness and factors associated with rotavirus vaccine uptake among Australian Aboriginal and non-Aboriginal children: a record linkage cohort study. Vaccine. 2019;37(39):5835–43. doi: https://doi.org/10.1016/j.vaccine.2019.08.013.
Patel MM, Clark AD, Sanderson CFB, Tate J, Parashar UD. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med. 2012;9(10):e1001330. doi: https://doi.org/10.1371/journal.pmed.1001330.
Middleton BF, Danchin M, Jones MA, Leach AJ, Cuncliffe N, Kirkwood CD et al. Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants to improve protection against gasteroenteritis: a phase IV, double-blind, randomised, placebo-controlled clinical trial. J Infect Dis. 2022;jiac038. doi: https://doi.org/10.1093/infdis/jiac038.
Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016. doi: https://doi.org/10.1038/nrdp.2015.16.
Marshall HS, McIntyre P, Richmond P, Buttery JP, Royle JA, Gold MS et al. Changes in patterns of hospitalized children with varicella and of associated varicella genotypes after introduction of varicella vaccine in Australia. Pediatr Infect Dis J. 2013;32(5):530–7. doi: https://doi.org/10.1097/INF.0b013e31827e92b7.
Cohen EJ, Jeng BH. Herpes zoster: a brief definitive review. Cornea. 2021;40(8):943–9. doi: https://doi.org/10.1097/ICO.0000000000002754.
Cunningham AL, Breuer J, Dwyer DE, Gronow DW, Helme RD, Litt JC et al. The prevention and management of herpes zoster. Med J Aust. 2008;188(3):171–6. doi: https://doi.org/10.5694/j.1326-5377.2008.tb01566.x.
Teutsch SM, Nunez CA, Morris A, McGregor S, King J, Brotherton JM et al. Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.60.
Sheridan SL, Quinn HE, Hull BP, Ware RS, Grimwood K, Lambert SB. Impact and effectiveness of childhood varicella vaccine program in Queensland, Australia. Vaccine. 2017;35(27):3490–7. doi: https://doi.org/10.1016/j.vaccine.2017.05.013.
Quinn HE, Gidding HF, Marshall HS, Booy R, Elliott EJ, Richmond P et al. Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program. J Infect. 2019;78(3):220–5. doi: https://doi.org/10.1016/j.jinf.2018.11.009.
AIHW. Indigenous health and wellbeing: life expectancy and deaths. [Webpage.] Canberra: Australian Government, AIHW; 2020. [Accessed on 27 October 2021.] Available from: https://www.aihw.gov.au/reports/australias-health/indigenous-health-and-wellbeing#Life%20expectancy%20and%20deaths.
Sheel M, Beard FH, Dey A, Macartney K, McIntyre PB. Rates of hospitalisation for herpes zoster may warrant vaccinating Indigenous Australians under 70. Med J Aust. 2017;207(9):395–6. doi: https://doi.org/10.5694/mja16.01468.
Dey A, Wang H, Beard F, Macartney K, McIntyre P. Summary of national surveillance data on vaccine preventable diseases in Australia, 2012–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.58.
Tiwari TSP, Wharton M. 19 – Diphtheria toxoid. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;261–75.e7. doi: https//doi.org/10.1016/B978-0-323-35761-6.00019-5.
Winkler NE, Dey A, Quinn HE, Pourmarzi D, Lambert S, McIntyre P et al. Australian vaccine preventable disease epidemiological review series: diphtheria, 1999–2019. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.42.
Roper MH, Wassilak SGF, Scobie HM, Ridpath AD, Orenstein WA. 58 – Tetanus toxoid. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;1052–79.e18. doi: https//doi.org/10.1016/B978-0-323-35761-6.00058-4.
Quinn HE, McIntyre PB. Tetanus in the elderly—an important preventable disease in Australia. Vaccine. 2007;25(7):1304–9. doi: https://doi.org/10.1016/j.vaccine.2006.09.084.
Sutter RW, Kew OM, Cochi SL, Aylward RB. 49 – Poliovirus vaccine–live. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;866–917.e16. doi: https//doi.org/10.1016/B978-0-323-35761-6.00048-1.
Hall JJ, Ambang T, Asante A, Mapira P, Craig A, Schuele E et al. Poliomyelitis outbreak in Papua New Guinea: health system and health security implications for PNG and Australia. Med J Aust. 2019;211(4):161–2.e1. doi: https://doi.org/10.5694/mja2.50283.
Bao J, Thorley B, Isaacs D, Dinsmore N, Elliott EJ, McIntyre P et al. Polio – the old foe and new challenges: an update for clinicians. J Paediatr Child Health. 2020;56(10):1527–32. doi: https://doi.org/10.1111/jpc.15140.
Dwyer DE, Robertson PW, Field PR, Board of Education of the Royal College of Pathologists of Australasia. Broadsheet: clinical and laboratory features of rubella. Pathology. 2001;33(3):322–8.
Song N, Gao Z, Wood JG, Hueston L, Gilbert GL, MacIntyre CR et al. Current epidemiology of rubella and congenital rubella syndrome in Australia: progress towards elimination. Vaccine. 2012;30(27):4073–8. doi: https://doi.org/10.1016/j.vaccine.2012.04.025.
Reef SE, Plotkin SA. 53 – Rubella vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;970–1000.e18. doi: https//doi.org/10.1016/B978-0-323-35761-6.00052-3.
Deverell M, Phu A, Zurynski YA, Elliott EJ. Australian Paediatric Surveillance Unit annual report, 2015. Commun Dis Intell Q Rep. 2017;41(2):E181–5.
Gidding H, Dey A, Macartney K. Australia has eliminated rubella – but that doesn’t mean it can’t come back. [Internet.] Melbourne: The Conversation Media Group, The Conversation Australia and New Zealand; 2 November 2018. [Accessed on 26 September 2022.] Available from: https://theconversation.com/australia-has-eliminated-rubella-but-that-doesnt-mean-it-cant-come-back-106056.
Chan J, Dey A, Wang H, Martin N, Beard F. Australian vaccine preventable disease epidemiological review series: rubella 2008–2012. Commun Dis Intell Q Rep. 2015;39(1):E19–26.
Hull BP, McIntyre PB, Heath TC, Sayer GP. Measuring immunisation coverage in Australia. A review of the Australian Childhood Immunisation Register. Aust Fam Physician. 1999;28(1):55–60.
Australian Government Department of Health and Aged Care. Immunise Australia Program: Expansion of Registers. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2016. [Accessed on 21 October 2016.] Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/expansion-registers.
Hull B, Deeks S, Menzies R, McIntyre P. Immunisation coverage annual report, 2007. Commun Dis Intell Q Rep. 2009;33(2):170–87.
Hull BP, Dey A, Menzies RI, Brotherton JM, McIntyre PB. Immunisation coverage, 2012. Commun Dis Intell Q Rep. 2014;38(3):E208–31.
NCIRS. No Jab No Play, No Jab No Pay. [Internet.] Sydney: NCIRS; 2021. [Accessed on 13 December 2021.] Available from: https://www.ncirs.org.au/public/no-jab-no-play-no-jab-no-pay.
Australian Government Department of Health and Aged Care. No Jab No Pay new requirements fact sheet. Canberra: Australian Government Department of Health and Aged Care; 14 October 2020. [Accessed on 13 December 2021.] Available from: https://www.health.gov.au/resources/publications/no-jab-no-pay-new-requirements-fact-sheet.
Thomas P, Joseph TL, Menzies RI. Evaluation of a targeted immunisation program for Aboriginal and Torres Strait Islander infants in an urban setting. NSW Public Health Bull. 2008;19(5–6):96–9. doi: https://doi.org/10.1071/nb07055.
Cashman PM, Allan NA, Clark KK, Butler MT, Massey PD, Durrheim DN. Closing the gap in Australian Aboriginal infant immunisation rates – the development and review of a pre-call strategy. BMC Public Health. 2016;16:514. doi: https://doi.org/10.1186/s12889-016-3086-x.
Hendry AJ, Beard FH, Dey A, Meijer D, Campbell-Lloyd S, Clark KK et al. Closing the vaccination coverage gap in New South Wales: the Aboriginal Immunisation Healthcare Worker Program. Med J Aust. 2018;209(1):24–8. doi: https://doi.org/10.5694/mja18.00063.
Brisson M, Bénard E, Drolet M, Bogaards JA, Baussano I, Vänskä S et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8–17. doi: https://doi.org/10.1016/S2468-2667(16)30001-9.
Australian Government Department of Health and Aged Care. CDNA surveillance case definitions. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 2021. [Accessed on 13 December 2021.] Available from: https://www.health.gov.au/resources/collections/cdna-surveillance-case-definitions.
NNDSS Annual Report Working Group. Australia’s notifiable disease status, 2016: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.28.
AIHW. Improving the quality of Indigenous identification in hospital separations data. (Cat. No. HSE 101.) Canberra: Australian Government, AIHW; 9 December 2005. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/indigenous-australians/improving-identification-hospital-separation-data/contents/table-of-contents.
O’Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005;40(5 Pt 2):1620–39. doi: https://doi.org/10.1111/j.1475-6773.2005.00444.x.
Australian Bureau of Statistics. Causes of death: Australia (Reference period 2019). [Webpage.] Canberra; Australian Bureau of Statistics; 23 October 2020. Available from: https://www.abs.gov.au/statistics/health/causes-death/causes-death-australia/2019.
AIHW. Mortality over the twentieth century in Australia: trends and patterns in major causes of death. (Cat. no. PHE 73.) Canberra: Australian Government, AIHW; 5 April 2006. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/life-expectancy-deaths/mortality-twentieth-century-australia-trends/summary.
Pinto Carvalho FL, Cordeiro JA, Cury PM. Clinical and pathological disagreement upon the cause of death in a teaching hospital: analysis of 100 autopsy cases in a prospective study. Pathol Int. 2008;58(9):568–71. doi: https://doi.org/10.1111/j.1440-1827.2008.02272.x.
Crowcroft NS, Andrews N, Rooney C, Brisson M, Miller E. Deaths from pertussis are underestimated in England. Arch Dis Child. 2002;86(5):336–8. doi: https://doi.org/10.1136/adc.86.5.336.
Sutter RW, Cochi SL, Brink EW, Sirotkin BI. Assessment of vital statistics and surveillance data for monitoring tetanus mortality, United States, 1979–1984. Am J Epidemiol. 1990;131(1):132–42. doi: https://doi.org/10.1093/oxfordjournals.aje.a115466.
AIHW. Principles on the use of direct age-standardisation in administrative data collections: for measuring the gap between Indigenous and non-Indigenous Australians. (Cat. no. CSI 12.) Canberra: Australian Government, AIHW; 7 October 2011. [Accessed on 26 September 2022.] Available from: https://www.aihw.gov.au/reports/indigenous-australians/principles-on-the-use-of-direct-age-standardisatio/summary.
Australian Bureau of Statistics. National, state and territory population (Reference period December 2020). [Webpage.] Canberra: Australian Bureau of Statistics; 17 June 2021. [Accessed on 13 December 2021.] Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/dec-2020.
O’Brien ED, Sam GA, Mead C. Methodology for measuring Australia’s childhood immunisation coverage. Commun Dis Intell. 1998;22(3):36–7.
Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Estimating immunisation coverage: is the ‘third dose assumption’ still valid? Commun Dis Intell Q Rep. 2003;27(3):357–61.
Hull BP, McIntyre PB. Immunisation coverage reporting through the Australian Childhood Immunisation Register – an evaluation of the third-dose assumption. Aust N Z J Public Health. 2000;24(1):17–21. doi: https://doi.org/10.1111/j.1467-842x.2000.tb00717.x.
Australian Bureau of Statistics. Australian Statistical Geography Standard (ASGS). [Webpage.] Canberra: Australian Bureau of Statistics; 2011. [Accessed on 17 November 2014.] Available from: http://www.abs.gov.au/websitedbs/d3310114.nsf/home/australian+statistical+geography+standard+%28asgs%29.
MapInfo. MapInfo Pro version 15.0. [Software.] Pitney Bowes Software, Stamford, Connecticut, USA; 2015.
Australian Bureau of Statistics. 1270.0.55.006 – Australian Statistical Geography Standard (ASGS): Correspondences, July 2011. (Cat. no. 1270.0.55.006.) [Webpage.] Canberra: Australian Bureau of Statistics; 27 June 2012. [Accessed on 17 November 2014.] Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/1270.0.55.006Main+Features1July%202011.
Hugo Centre for Migration and Population Research. Accessibility/Remoteness Index of Australia - ARIA++(2011). [Internet.] Adelaide: University of Adelaide, Hugo Centre for Migration and Population Research, 2011. [Accessed on 17 November 2017.] Available from: https://www.adelaide.edu.au/hugo-centre/spatial_data/.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
